AbbVie to Host Second-Quarter 2025 Earnings Conference Call
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Morgan Stanley on Abbvie (ABBV) Buying Capstan: 'We view this acquisition as an incremental positive'
June 30, 2025 12:48 PM EDTMorgan Stanley analyst Terrance Flynn reiterated an Overweight rating and $250.00 price target on Abbvie (NYSE: ABBV).
The analyst comments "ABBV announced on 6/30 an agreement to acquire Capstan Therapeutics (private), a clinical-stage biotech focused on engineering cells in vivo (such as CAR-T) through RNA... More
